Print

Purpose

The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Provide written, informed consent to participate in the study and follow the study procedures - Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 - Measurable disease per RECIST 1.1 criteria - Histologically or cytologically documented inoperable, locally advanced or metastatic urothelial cell carcinoma (also termed TCC) - Fresh biopsy or archival tissue - No prior systemic chemotherapy or investigational agent for inoperable locally advanced or mUC - Ineligible for cisplatin

Exclusion Criteria

  • Patients who have an active, known or suspected autoimmune disease - Patients must not have received prior IL-2 therapy - Prior treatment with an anti PD-1, anti PD-L1, or anti cytotoxic T lymphocyte associated protein 4 (anti CTLA-4) antibody, agents that target IL-2 pathway, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways - Patients with hypertension must be on a stable antihypertensive regimen for the 14 days prior to Cycle 1 Day 1 Additional protocol-defined inclusion/exclusion criteria applied

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Combination of bempegaldesleukin (NKTR-214) + nivolumab 		Participants will receive bempegaldesleukin (NKTR-214) in combination with nivolumab.
  • Biological: Bempegaldesleukin
    Specified dose on specified days
    Other names:
    • NKTR-214
    • BMS-986321
  • Biological: Nivolumab
    Specified dose on specified days
    Other names:
    • Opdivo®
    • BMS-936658

More Details

Status
Completed
Sponsor
Nektar Therapeutics

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.